DeichmannA., BrugmanM.H., BartholomaeC.C., et al. (2011). Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol. Ther., 19, 2031–2039.
2.
GasparH.B., CoorayS., GilmourK.C., et al. (2011). Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med., 3, 97ra80.
3.
GasparH.B., CoorayS., GilmourK.C., et al. (2011). Long-term persistence of a polyclonal T cell repertoire after gene therapy for x-linked severe combined immunodeficiency. Sci. Transl. Med., 3, 97ra79.
4.
HustonM.W., van TilN.P., VisserT.P., et al. (2011). Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol. Ther., 19, 1867–1877.
5.
SantilliG., AlmarzaE., BrendelC., et al. (2011). Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol. Ther., 19, 122–132.
6.
AiutiA., BacchettaR., SegerR., et al. (2012). Gene therapy for primary immunodeficiencies: part 2. Curr. Opin. Immunol., 24, 585–591.
7.
HecklD., SchwarzerA., HaemmerleR., et al. (2012). Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol. Ther., 20, 1187–1195.
8.
ItkinT., LudinA., GradusB., et al. (2012). FGF-2 expands murine hematopoietic stem and progenitor cells via proliferation of stromal cells, c-Kit activation and CXCL12 down regulation. Blood, 120, 1843–1855.
9.
LudinA., ItkinT., Gur-CohenS., et al. (2012). αSMA+monocytes/macrophages preserve ROSlow primitive hematopoietic cell pool in the bone marrow in a Cox-2 dependent manner. Nat. Immunol., 13, 1072–1082.
10.
MarrellaV., PolianiP.L., FontanaE., et al. (2012). Anti-CD3ɛ mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. Blood, 120, 1005–1014.
11.
ReimannC., SixE., Dal-CortivoL., et al. (2012). Human T-lymphoid progenitors generated in a feeder-cell-free delta-4 culture system promote t-cell reconstitution in NOD/SCID/γc(−/−) mice. Stem Cells, 30, 1771–1780.
12.
SauerA.V., MorbachH., BrigidaI., et al. (2012). Defective B cell tolerance due to adenosine deaminase deficiency is corrected by gene therapy. J. Clin. Invest., 122, 2141–2152.
13.
ScaramuzzaS., BiascoL., RipamontiA., et al. (2012). Preclinical safety and efficacy on human CD34+ cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther., 21, 175–184.
14.
SuerthJ.D., MaetzigT., BrugmanM.H., et al. (2012). Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol. Ther., 20, 1022–1032.
15.
van der LooJ.C., SwaneyW.P., GrassmanE., et al. (2012). Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency. Gene Ther., 19, 872–876.
16.
van TilN.P., de BoerH., MashambaN., et al. (2012). Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol. Ther., 20, 1968–1980.
17.
AiutiA., BiascoL., ScaramuzzaS., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 1233151.
18.
CarbonaroD.A., ZhangL., JinX., et al. (2013). Pre-clinical demonstration of lentiviral vector mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol. Ther., 22, 607–622.
19.
KaufmannK.B., BrendelC., SuerthJ.D., et al. (2013). Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol. Ther., 21, 648–661.
20.
PasseriniL., MelE.R., SartiranaC., et al. (2013). CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. Sci. Transl. Med., 5, 215ra174.
21.
van TilN.P., SarwariR., VisserT.P., et al. (2013). Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J. Allergy Clin. Immunol., 133, 1116–1123.
22.
GrinenkoT., ArndtK., PortzM., et al. (2014). Clonal expansion capacity defines two consecutive developmental stages of long-term hematopoietic stem cells. J. Exp. Med., 211, 209–215.
